Engineering Magnetosomes for High-Performance Cancer Vaccination

Feng Li; Weidong Nie; Fan Zhang; Guihong Lu; Chengliang Lv; Yanlin Lv; Weier Bao; Lijun Zhang; Shuang Wang; Xiaoyong Gao; Wei Wei; Hai Yan Xie

doi:10.1021/acscentsci.9b00060

Engineering Magnetosomes for High-Performance Cancer Vaccination

Feng Li, Weidong Nie, Fan Zhang, Guihong Lu, Chengliang Lv, Yanlin Lv, Weier Bao, Lijun Zhang, Shuang Wang, Xiaoyong Gao, Wei Wei^*, Hai Yan Xie

^*Corresponding author for this work

School of Life Science

Research output: Contribution to journal › Article › peer-review

87 Citations (Scopus)

Abstract

A novel cancer vaccine is developed by using Fe₃O₄ magnetic nanoclusters (MNCs) as the core and cancer cell membranes decorated with anti-CD205 as the cloak. Because of the superparamagnetism and magnetization of MNCs, it is first achieved for the magnetic retention of vaccine in the lymph nodes with a magnetic resonance imaging (MRI) guide, which opened the time window for antigen uptake by dendritic cells (DCs). Meanwhile, the camouflaged cancer cell membranes serve as a reservoir of various antigens, enabling subsequent multiantigenic response. Additionally, the decorated anti-CD205 direct more vaccine into CD8⁺ DCs, facilitating the major histocompatibility complex (MHC) I cross-presentation. These unique advantages together lead to a great proliferation of T cells with superior clonal diversity and cytotoxic activity. As a result, potent prophylactic and therapeutic effects with few abnormalities are observed on five different tumor models. Therefore, such a cancer-derived magnetosome with the integration of various recent nanotechnologies successfully demonstrates its promise for safe and high-performance cancer vaccination.

Original language	English
Pages (from-to)	796-807
Number of pages	12
Journal	ACS Central Science
Volume	5
Issue number	5
DOIs	https://doi.org/10.1021/acscentsci.9b00060
Publication status	Published - 22 May 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/acscentsci.9b00060

Cite this

Li, F., Nie, W., Zhang, F., Lu, G., Lv, C., Lv, Y., Bao, W., Zhang, L., Wang, S., Gao, X., Wei, W., & Xie, H. Y. (2019). Engineering Magnetosomes for High-Performance Cancer Vaccination. ACS Central Science, 5(5), 796-807. https://doi.org/10.1021/acscentsci.9b00060

@article{c4c169037f484cc09304f512a00125f1,

title = "Engineering Magnetosomes for High-Performance Cancer Vaccination",

abstract = "A novel cancer vaccine is developed by using Fe3O4 magnetic nanoclusters (MNCs) as the core and cancer cell membranes decorated with anti-CD205 as the cloak. Because of the superparamagnetism and magnetization of MNCs, it is first achieved for the magnetic retention of vaccine in the lymph nodes with a magnetic resonance imaging (MRI) guide, which opened the time window for antigen uptake by dendritic cells (DCs). Meanwhile, the camouflaged cancer cell membranes serve as a reservoir of various antigens, enabling subsequent multiantigenic response. Additionally, the decorated anti-CD205 direct more vaccine into CD8+ DCs, facilitating the major histocompatibility complex (MHC) I cross-presentation. These unique advantages together lead to a great proliferation of T cells with superior clonal diversity and cytotoxic activity. As a result, potent prophylactic and therapeutic effects with few abnormalities are observed on five different tumor models. Therefore, such a cancer-derived magnetosome with the integration of various recent nanotechnologies successfully demonstrates its promise for safe and high-performance cancer vaccination.",

author = "Feng Li and Weidong Nie and Fan Zhang and Guihong Lu and Chengliang Lv and Yanlin Lv and Weier Bao and Lijun Zhang and Shuang Wang and Xiaoyong Gao and Wei Wei and Xie, {Hai Yan}",

note = "Publisher Copyright: Copyright {\textcopyright} 2019 American Chemical Society.",

year = "2019",

month = may,

day = "22",

doi = "10.1021/acscentsci.9b00060",

language = "English",

volume = "5",

pages = "796--807",

journal = "ACS Central Science",

issn = "2374-7943",

publisher = "American Chemical Society",

number = "5",

}

TY - JOUR

T1 - Engineering Magnetosomes for High-Performance Cancer Vaccination

AU - Li, Feng

AU - Nie, Weidong

AU - Zhang, Fan

AU - Lu, Guihong

AU - Lv, Chengliang

AU - Lv, Yanlin

AU - Bao, Weier

AU - Zhang, Lijun

AU - Wang, Shuang

AU - Gao, Xiaoyong

AU - Wei, Wei

AU - Xie, Hai Yan

PY - 2019/5/22

Y1 - 2019/5/22

N2 - A novel cancer vaccine is developed by using Fe3O4 magnetic nanoclusters (MNCs) as the core and cancer cell membranes decorated with anti-CD205 as the cloak. Because of the superparamagnetism and magnetization of MNCs, it is first achieved for the magnetic retention of vaccine in the lymph nodes with a magnetic resonance imaging (MRI) guide, which opened the time window for antigen uptake by dendritic cells (DCs). Meanwhile, the camouflaged cancer cell membranes serve as a reservoir of various antigens, enabling subsequent multiantigenic response. Additionally, the decorated anti-CD205 direct more vaccine into CD8+ DCs, facilitating the major histocompatibility complex (MHC) I cross-presentation. These unique advantages together lead to a great proliferation of T cells with superior clonal diversity and cytotoxic activity. As a result, potent prophylactic and therapeutic effects with few abnormalities are observed on five different tumor models. Therefore, such a cancer-derived magnetosome with the integration of various recent nanotechnologies successfully demonstrates its promise for safe and high-performance cancer vaccination.

AB - A novel cancer vaccine is developed by using Fe3O4 magnetic nanoclusters (MNCs) as the core and cancer cell membranes decorated with anti-CD205 as the cloak. Because of the superparamagnetism and magnetization of MNCs, it is first achieved for the magnetic retention of vaccine in the lymph nodes with a magnetic resonance imaging (MRI) guide, which opened the time window for antigen uptake by dendritic cells (DCs). Meanwhile, the camouflaged cancer cell membranes serve as a reservoir of various antigens, enabling subsequent multiantigenic response. Additionally, the decorated anti-CD205 direct more vaccine into CD8+ DCs, facilitating the major histocompatibility complex (MHC) I cross-presentation. These unique advantages together lead to a great proliferation of T cells with superior clonal diversity and cytotoxic activity. As a result, potent prophylactic and therapeutic effects with few abnormalities are observed on five different tumor models. Therefore, such a cancer-derived magnetosome with the integration of various recent nanotechnologies successfully demonstrates its promise for safe and high-performance cancer vaccination.

UR - http://www.scopus.com/inward/record.url?scp=85064402987&partnerID=8YFLogxK

U2 - 10.1021/acscentsci.9b00060

DO - 10.1021/acscentsci.9b00060

M3 - Article

AN - SCOPUS:85064402987

SN - 2374-7943

VL - 5

SP - 796

EP - 807

JO - ACS Central Science

JF - ACS Central Science

IS - 5

ER -

Engineering Magnetosomes for High-Performance Cancer Vaccination

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this